Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

Antibodies against epitopes in S1 give the most accurate CoP against infection by the SARS‐
CoV‐2 coronavirus. Measurement of those antibodies by neutralization or binding assays …

Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …

The potential for future coronavirus outbreaks highlights the need to broadly target this
group of pathogens. We used an epitope-agnostic approach to identify six monoclonal …

Pre-existing cross-reactive immune responses to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

Frequent outbreaks of coronaviruses underscore the need for antivirals and vaccines that
can counter a broad range of coronavirus types. We isolated a human antibody named 76E1 …

The coronavirus spike glycoprotein attaches to host receptors and mediates viral fusion.
Using a broad screening approach, we isolated seven monoclonal antibodies (mAbs) that …

Numerous safe and effective coronavirus disease 2019 vaccines have been developed
worldwide that use various delivery technologies and engineering strategies. We show here …